Blood test predicts which kids may benefit from autism drug

NCT ID NCT07005414

Completed Symptom relief Sponsor: Fei Li Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether bumetanide, a diuretic, can improve social skills in children with autism. Researchers used a blood test and machine learning to pick children likely to respond. 66 children aged 3-6 took bumetanide or standard behavioral therapy for three months. The goal was to see if social symptoms improved more with the drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bumetanide
What this could lead to: If it works, this could point toward a personalized treatment for social impairment in some children with autism.
What could go wrong: This is a small Phase 2 trial with only 66 children, so results may not apply to everyone. Bumetanide is a diuretic and can cause side effects like dehydration or electrolyte imbalance.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTISM SPECTRUM DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autism spectrum disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTISM SPECTRUM DISORDER

Contacts and locations

Locations

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Shanghai, Shanghai Municipality, 200092, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.